Hugel, Inc. (KOSDAQ:145020)

South Korea flag South Korea · Delayed Price · Currency is KRW
336,500
+4,500 (1.36%)
Jun 2, 2025, 3:30 PM KST
76.18%
Market Cap 3.42T
Revenue (ttm) 388.56B
Net Income (ttm) 144.07B
Shares Out 10.16M
EPS (ttm) 12,769.16
PE Ratio 26.35
Forward PE 27.69
Dividend n/a
Ex-Dividend Date n/a
Volume 37,834
Average Volume 68,337
Open 332,500
Previous Close 332,000
Day's Range 330,000 - 340,500
52-Week Range 194,000 - 377,000
Beta 0.33
RSI 44.71
Earnings Date May 7, 2025

About Hugel

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o... [Read more]

Industry Pharmaceutical Preparations
Founded 2001
Employees 594
Stock Exchange KOSDAQ
Ticker Symbol 145020
Full Company Profile

Financial Performance

In 2024, Hugel's revenue was 373.05 billion, an increase of 16.69% compared to the previous year's 319.70 billion. Earnings were 135.81 billion, an increase of 45.92%.

Financial Statements

News

Hugel hits record net sales, operating profit in Q3

- Net sales registered KRW105.1 billion and operating profit achieved KRW53.4 billion , up 23.9% and 54.5% on-year, respectively - Net sales of toxin rose 41% on-year, thanks to initial shipment to th...

7 months ago - Benzinga